Check Pricing Near You
Provider Login
Become a Price Transparent Provider

BuildMyBod on Becker’s ASC Keynote Panel

becker's asc
Dr. Kaplan continues his trek across the country from San Francsico to Dallas to Chicago for the Becker’s ASC meeting. While in Chicago he will serve on two panels. First, the annual Keynote Panel along with other key opinion leaders in healthcare on Thursday. Second, a panel on Price Transparency on Friday.


Becker’s ASC Keynote Panel

Topics for discussion on the Keynote Panel include, trends in the ambulatory surgery center (ASC) industry. While all of Dr. Kaplan’s comments will be from the perspective of price transparency, that leads to several major buzzwords. Price transparency leads to patient engagement and improved customer service. And with the help of the BuildMyBod Health platform, this also results in lead generation, patient follow up, patient education and patient navigation. No shortage of buzzwords here!


Price Transparency Panel

The price transparency panel will include ASC administrators and doctors that believe in price transparency. Panel members will discuss how price transparency has been a benefit to their practice or facility. However, the other panel members showcase price transparency with a menu of procedures and their prices.


This provides no lead generation and no way for the facility to follow up with the consumer to provide more education. This is the critical piece missing in the price transparency debate. If you provide consumers with information that is broad, vague and inactionable, it’s no different than providing them with no information at all. Using price transparency to connect the consumer with the facility through lead generation is what will really transform healthcare.


For more information on BuildMyBod Health, price transparency and lead generation, click here.




Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts


Update on Breast Implants

The Food and Drug Administration (FDA) released a new safety communication about squamous cell carcinoma (SCC) and various lymphomas in the capsule around breast implants.